Nyxoah Rings the Closing Bell at Nasdaq while Preparing for U.S. Market Launch of Innovative Sleep Apnea Device FDA regulatory submission for the Company’s Genio® device is complete, U.S. approval on track for the end of 2024 U.S. commercial launch, expected at the beginning of 2025, fully funded with over €85 million in new capital [...]
REGULATED INFORMATION Nyxoah Reports Second Quarter and First Half 2024 Financial and Operating Results FDA regulatory submission complete, U.S. approval on track for end of 2024 U.S. commercial launch fully funded with over €85 million in new capital raised Mont-Saint-Guibert, Belgium, Aug. 6 (Korea Bizwire) – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a [...]
Nyxoah to Release Second Quarter and First Half 2024 Financial Results on August 6, 2024 Mont-Saint-Guibert, Belgium, Jul. 29 (Korea Bizwire) – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company will release [...]
Mont-Saint-Guibert, Belgium – July 15, 2024, 8:00am CET / 2:00am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced the appointment of Scott Holstine as Chief Commercial Officer. In this role, Scott will [...]
REGULATED INFORMATION INSIDE INFORMATION Nyxoah Has Signed a €37.5 Million Loan Facility Agreement with the European Investment Bank Mont-Saint-Guibert, Belgium – July 3, 2024, 12:30pm CET / 6:30am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea [...]
Nyxoah Submits Fourth and Final Module in PMA Application for Genio to the US FDA Mont-Saint-Guibert (Belgium), July 1, 2024, 8:00am CET / 2:00am ET – (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company submitted the fourth and final module [...]
Information on the total number of voting rights and shares Mont-Saint-Guibert (Belgium), June 28, 2024, 10:30 pm CET / 4:30 pm ET – In accordance with article 15 of the Law of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels and Nasdaq: NYXH) publishes the below information following the issue of new shares. Share capital: EUR 5,904,962.41 Total number of securities [...]
Mont-Saint-Guibert, Belgium, Jun. 3 (Korea Bizwire) – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company will participate in the Jefferies Global Healthcare Conference, which takes place June 5 – 6, 2024 [...]
REGULATED INFORMATION Information on the total number of voting rights and shares Mont-Saint-Guibert, Belgium, Jun. 3 (Korea Bizwire) – In accordance with article 15 of the Law of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels and Nasdaq: NYXH) publishes the below information following the issue of new shares. Share capital: EUR 5,902,793.43 Total number of securities carrying voting rights: [...]
REGULATED INFORMATION Publication relating to transparency notifications Mont-Saint-Guibert, Belgium, Jun. 3 (Korea Bizwire) – In accordance with article 14 of the Act of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) announces that it received four transparency notifications as detailed below. FMR LLC On May 30, 2024, Nyxoah received a transparency notification from FMR LLC following [...]